IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19.
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19.
复制标题
DOI：
10.1016/s2665-9913(21)00321-0
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
COVID-BioB study group
中科院分区：
文献类型：
--
作者：
Della-Torre E;Criscuolo E;Lanzillotta M;Locatelli M;Clementi N;Mancini N;Dagna L;COVID-BioB study group
淋巴器官中IL-6表达的时空动态影响抗病毒体液免疫和细胞适应性免疫之间的平衡。1特别是，细胞病变病毒通常诱导IL-6介导的幼稚CD 4 + T细胞分化为滤泡辅助T细胞，促进产生有效的中和抗体应答。1 SARS-CoV-2（COVID-19大流行的病原体）是一种细胞病变病毒，可导致危及生命的肺炎，其特征是适应不良的炎症反应，血清IL-6水平较高与疾病严重程度相关。2，3值得注意的是，从严重形式的COVID-19中恢复的患者产生了最有效的抗SARS-CoV-2中和抗体，并且正在研究这些个体的恢复期血浆，以获得用于治疗目的的单克隆抗体。4然而，拮抗IL-6的治疗方法从大流行开始就被重新利用，目前已被批准用于治疗严重的COVID-19住院患者。5鉴于IL-6在中和抗病毒体液免疫的发展中的关键作用，我们评估了抗SARS-CoV-2抗体的滴度及其在使用IL-6抑制剂治疗的危及生命的COVID-19康复患者中随时间推移的中和能力。研究了在San Raffaele医院（意大利米兰）住院的30名患有严重COVID-19肺炎伴炎症过度的患者。10例患者接受当地标准治疗，10例患者接受抗IL-6受体单克隆抗体sar治疗
Spatiotemporal dynamics of interleukin (IL)-6 expression in lymphoid organs influence the balance between antiviral humoral and cellular adaptive immunity. 1 In particular, cytopathic viruses typically induce IL-6-mediated differentiation of naive CD4+ T cells into follicular helper T-cells, facilitating the production of potent neutralising antibody responses. 1 SARS-CoV-2 (the causal agent of the COVID-19 pandemic) is a cytopathic virus that can cause a lifethreatening pneumonia characterised by a maladaptive inflammatory response whereby higher levels of serum IL-6 correlate with disease severity. 2, 3 Notably, patients who have recovered from severe forms of COVID-19 develop the most effective anti-SARS-CoV-2 neutralising antibodies, and convalescent plasma from these individuals is being studied to derive monoclonal antibodies for therapeutic purposes. 4 Yet, treatments that antagonise IL-6 have been repurposed from the beginning of the pandemic and are currently approved for the treatment of inpatients with severe COVID-19. 5 Given the crucial role of IL-6 in the development of neutralising antiviral humoral immunity, we assessed the titre of anti-SARS-CoV-2 antibodies and their neutralising capacity over time in patients recovered from life-threatening COVID-19 treated with IL-6 inhibitors. 30 patients admitted at San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia with hyperinflammation were studied. Ten patients were treated with local standard of care and ten with the anti-IL-6 receptor monoclonal antibodies sarilumab